Neutralizing antibodies that bind to the zika virus domain III envelope region
AssigneeThe Rockefeller University
InventorsDavide Robbiani, Michel Nussenzweig
Life of this patent
Estimating the term…
Abstract
Antibodies to Zika virus (ZIKV) and dengue 1 virus (DENV1) are provided. The amino acid sequences of the antibodies may be modified. Methods for prophylaxis and/or therapy by administering the antibodies and combinations thereof are provided. Immunological detection methods using the antibodies are provided. Also provided are vaccine compositions which comprise peptides derived from ZIKV and DENV1.
Claims7
A recombinant antibody, said antibody comprising a heavy chain comprising the sequence:
- EVQLLESGGGLVQPGGSLRLTCATSGFTFRDYAMSWVRQAPGKGLEWVSSYSGIDDST YYADSVKGRFTISRDNSKSTLSLHMNSLRAEDSALYFCAKDRGPRGVGELFDSWGQGT LVTVSS (SEQ ID NO:11), and a light chain comprising the sequence:
- DIQMTQSPSTLSASVGDRVTITCRASQSISKWLAWYQQKPGKAPKLLIYTTSTLKSGVPS RFSGSGSGTEFTLTISSLQPDDFATYYCQHFYSVPWTFGQGTKVEIK (SEQ ID NO:
- 12).
An isolated and non-naturally occurring antibody that is capable of binding with specificity to the lateral ridge of Zika virus envelope Domain III protein, said antibody comprising a heavy chain comprising:
- a CDR1 comprising the sequence GFTFRDYA (SEQ ID NO:1), a CDR2 comprising the sequence YSGIDDST (SEQ ID NO:2), and a CDR3 comprising the sequence AKDRGPRGVGELFDS (SEQ ID NO:3), and a light chain comprising:
- a CDR1 comprising the sequence QSISKW (SEQ ID NO:4), a CDR2 comprising the sequence TTS, and a CDR3 comprising the sequence QHFYSVPWT (SEQ ID NO:5).
Dependencies are inferred from the claim text.